Cor Therapeutics: Dealmaking for the Marketplace
Executive Summary
Cor’s deal on Integrelin with Schering was the necessary keystone in its deal strategy but has also allowed the company to maintain momentum towards the marketplace despite the disappointing results of its Phase III trial.